Related Experiment Video
Updated: May 22, 2026
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Pemphigus vulgaris treated with adalimumab: case study
Naděžda Vojáčková1, Jorga Fialová, Daniela Vaňousová
1Department of Dermatovenereology, 2nd Medical School Charles University and Bulovka Hospital, Prague, Czech Republic. nadavojackova@seznam.cz
Dermatologic Therapy
|May 18, 2012
Summary
Adalimumab effectively treated pemphigus vulgaris, a severe blistering disease, in a patient experiencing side effects from traditional immunosuppressive therapy. This offers a promising alternative for managing difficult pemphigus vulgaris cases.
Area of Science:
- Immunodermatology
- Autoimmune Blistering Diseases
Background:
- Pemphigus vulgaris is a chronic autoimmune blistering disease affecting skin and mucous membranes.
- High mortality rates historically, now managed with corticosteroids.
- Corticosteroid-sparing agents are used to reduce steroid dosage and side effects.
